表紙
市場調查報告書

視黃酸受體伽馬:開發中產品分析

Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 557376
出版日期 內容資訊 英文 82 Pages
訂單完成後即時交付
價格
視黃酸受體伽馬:開發中產品分析 Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 82 Pages
簡介

本報告提供以視黃酸受體伽馬為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

視黃酸受體伽馬;概要

視黃酸受體伽馬;治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • 3SBio Inc
  • Boehringer Ingelheim GmbH
  • Clementia Pharmaceuticals Inc
  • Galderma SA
  • Lee's Pharmaceutical Holdings Ltd
  • Phosphagenics Ltd
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Valeant Pharmaceuticals International Inc

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2389TDB

Summary:

According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 17 molecules.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H1 2020' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 7, 1, 1, 7 and 1 respectively. Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Oncology, Ophthalmology, Respiratory, Gastrointestinal, Genetic Disorders, Immunology and Metabolic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Congenital Ichthyosis, Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Retinopathy Of Prematurity, Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to Buy:

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
  • Advent Therapeutics Inc
  • Avecho Biotechnology Ltd
  • Bausch Health Companies Inc
  • Boehringer Ingelheim International GmbH
  • Galderma SA
  • Ipsen SA
  • Lee's Pharmaceutical Holdings Ltd
  • Orphanix GmbH
  • Ortho Dermatologics Inc
  • Promius Pharma LLC
  • Sol-Gel Technologies Ltd
  • Sveikatal Inc
  • TherapyX Inc
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
  • (adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (adapalene + clindamycin hydrochloride) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (benzoyl peroxide + tretinoin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (benzoyl peroxide + tretinoin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (TPX-6001 + tretinoin) - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • alitretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • bexarotene + CD-1530 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • palovarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize ROR-Gamma for Autoimmune Disorders, Allergies and Spondylosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize RARG for Fibrosis - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tazarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tazarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tretinoin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • trifarotene - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vitamin A palmitate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • vitamin A palmitate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
  • Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
  • Featured News & Press Releases
  • Mar 27, 2020: Ipsen to restart dosing of palovarotene in FOP studies
  • Jan 27, 2020: Ipsen temporarily stops palovarotene dosing in FOP trials
  • Jan 21, 2020: Sol-Gel announces presentation on Twyneo at the 16th Annual Maui Derm for Dermatologists 2020 Meeting
  • Jan 13, 2020: Ortho Dermatologics announces publication of pivotal phase 3 data on ARAZLO (tazarotene) Lotion, 0.045% in the Journal of Drugs in Dermatology (JDD)
  • Jan 08, 2020: Certara partners with Galderma in advancing modeling and simulation technology to attain FDA approval of AKLIEF topical Acne cream
  • Jan 08, 2020: Sol-Gel hosts investor call to discuss positive results from Twyneo phase 3 program in Acne Vulgaris
  • Dec 30, 2019: Sol-Gel announces positive top-line phase 3 trial results of Twyneo for the treatment of acne vulgaris
  • Dec 20, 2019: Galderma receives a positive outcome through the European Decentralised Procedure for AKLIEF (trifarotene 50 mcg/g cream), the first new retinoid molecule for acne in the European Union in 25 years
  • Dec 19, 2019: FDA approves Ortho Dermatologics' ARAZLO (Tazarotene) lotion, 0.045%, for acne vulgaris
  • Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies
  • Nov 28, 2019: First new retinoid molecule approved in over 20 years
  • Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
  • Oct 15, 2019: Bausch Health's Ortho Dermatologics business to present data on acne drug tretinoin at The Fall Clinical Dermatology Conference
  • Oct 04, 2019: Galderma receives FDA approval for AKLIEF (trifarotene) cream, 0.005%, the first new retinoid molecule for the treatment of Acne in over 20 years
  • Aug 07, 2019: Ortho Dermatologics announces U.S. FDA filing acceptance for IDP-123 treatment for Acne Vulgaris in lotion form
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Indication, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Pipeline by Advent Therapeutics Inc, H1 2020
  • Pipeline by Avecho Biotechnology Ltd, H1 2020
  • Pipeline by Bausch Health Companies Inc, H1 2020
  • Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Pipeline by Galderma SA, H1 2020
  • Pipeline by Ipsen SA, H1 2020
  • Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2020
  • Pipeline by Orphanix GmbH, H1 2020
  • Pipeline by Ortho Dermatologics Inc, H1 2020
  • Pipeline by Promius Pharma LLC, H1 2020
  • Pipeline by Sol-Gel Technologies Ltd, H1 2020
  • Pipeline by Sveikatal Inc, H1 2020
  • Pipeline by TherapyX Inc, H1 2020
  • Dormant Products, H1 2020
  • Dormant Products, H1 2020 (Contd..1), H1 2020
  • Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development by Stage of Development, H1 2020
  • Number of Products under Development by Therapy Areas, H1 2020
  • Number of Products under Development by Top 10 Indications, H1 2020
  • Number of Products by Mechanism of Actions, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020